Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of telisotuzumab vedotin versus docetaxel in previously treated c-Met overexpressing EGFR-wild-type advanced non-squamous NSCLC
CTR20221935Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of telisotuzumab vedotin, docetaxel in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Started Jul 2023; status: active.
02
Drugs
telisotuzumab vedotindocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221935.